Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its ...

A phase 2b trial of HMNC Brain Health’s depression drug candidate has missed its primary endpoint. But while the ex-Sanofi molecule failed to move the needle in the overrall population, results in ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...

BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...